scholarly journals A comparative study between tinnitus masking and tinnitus retraining therapy on perceived tinnitus handicap and cognition

2020 ◽  
Vol 6 (6) ◽  
pp. 1091
Author(s):  
Indranil Chatterjee ◽  
Geeta Gore
Keyword(s):  
Prior History ◽  
Tinnitus Retraining Therapy ◽  
Long Term Effect ◽  
Initial Stage ◽  
Days Of Therapy ◽  
Retraining Therapy ◽  
History Of ◽  
Tinnitus Treatment ◽  
Group 2 ◽  
Tinnitus Masking

<p class="abstract"><strong>Background:</strong> Since last one decade there were no such studies done in India on the efficacy of tinnitus retraining therapy (TRT) on tinnitus treatment. Here, in this study we try to find out whether TRT is an effective tool than tinnitus masking as a treatment procedure of tinnitus in Indian context.</p><p class="abstract"><strong>Methods:</strong> A total of 60 participants (with no prior history of presence of hearing loss) were divided into two groups. Group 1 was consisted of 30 subjects provided tinnitus masking using relief app at the ease of their home environment for 2 months. Group 2 was consisted of another 30 subjects have been provided tinnitus retraining therapy (TRT) for 2months (60 sessions). The design is experimental design. The study was carried out in eight phases.  </p><p class="abstract"><strong>Results:</strong> The findings of this study suggested that both the tinnitus masking therapy as well as TRT helped tinnitus sufferers to improve after 60 days of therapy continuation at initial stage. But a significant marked difference was found in terms of performance in participants from group 2 who had undergone TRT i.e., they performed very well after one month of post transfer therapeutic sessions than those who had undergone tinnitus masking therapy.</p><p class="abstract"><strong>Conclusions:</strong> The findings of this study are suggestive of that TRT is more effective than tinnitus masking therapy in tinnitus individuals even after one month of stopping therapy sessions. It also suggests that TRT has a long-term effect on tinnitus management than tinnitus masking.</p>

Myeloid neoplasms in the setting of chronic lymphocytic leukaemia/chronic lymphocytic leukaemia-like disease: a clinicopathological study of 66 cases comparing cases with prior history of treatment to those without

2021 ◽  
pp. jclinpath-2020-207334
Author(s):  
Catherine Luedke ◽  
Yue Zhao ◽  
Jenna McCracken ◽  
Jake Maule ◽  
Lian-He Yang ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
The Other ◽  
Prior History ◽  
Myeloid Neoplasm ◽  
Myeloid Neoplasms ◽  
History Of ◽  
Cytogenetic Profile ◽  
Group 2 ◽  
Group 1

AimsMyeloid neoplasms occur in the setting of chronic lymphocytic leukaemia (CLL)/CLL-like disease. The underlying pathogenesis has not been elucidated.MethodsRetrospectively analysed 66 cases of myeloid neoplasms in patients with CLL/CLL-like disease.ResultsOf these, 33 patients (group 1) had received treatment for CLL/CLL-like disease, while the other 33 patients (group 2) had either concurrent diagnoses or untreated CLL/CLL-like disease before identifying myeloid neoplasms. The two categories had distinct features in clinical presentation, spectrum of myeloid neoplasm, morphology, cytogenetic profile and clinical outcome. Compared with group 2, group 1 demonstrated a younger age at the diagnosis of myeloid neoplasm (median, 65 vs 71 years), a higher fraction of myelodysplastic syndrome (64% vs 36%; OR: 3.1; p<0.05), a higher rate of adverse unbalanced cytogenetic abnormalities, including complex changes, −5/5q- and/or −7/7q- (83% vs 28%; OR: 13.1; p<0.001) and a shorter overall survival (median, 12 vs 44 months; p<0.05).ConclusionsMyeloid neoplasm in the setting of CLL/CLL-like disease can be divided into two categories, one with prior treatment for CLL/CLL-like disease and the other without. CLL-type treatment may accelerate myeloid leukaemogenesis. The risk is estimated to be 13-fold higher in patients with treatment than those without. The causative agent could be attributed to fludarabine in combination with alkylators, based on the latency of myeloid leukaemogenesis and the cytogenetic profile.

Comparison of Tinnitus Masking and Tinnitus Retraining Therapy

2002 ◽  
Vol 13 (10) ◽  
pp. 559-581 ◽  
Author(s):  
James A. Henry ◽  
Martin A. Schechter ◽  
Stephen M. Nagler ◽  
Stephen A. Fausti
Keyword(s):  
Clinical Application ◽  
Basic Component ◽  
Tinnitus Retraining Therapy ◽  
Basic Approach ◽  
Sound Therapy ◽  
The World ◽  
Considerable Confusion ◽  
International Attention ◽  
Retraining Therapy ◽  
Tinnitus Masking

Two methods for treating tinnitus are compared. Tinnitus masking has been used for over 25 years, and although this method is used in clinics around the world, there are many misconceptions regarding the proper protocol for its clinical application. Tinnitus retraining therapy has been used clinically for over 12 years and has received considerable international attention. Although these methods are distinctive in their basic approach to tinnitus management, certain aspects of treatment appear similar. These aspects of treatment have created considerable confusion and controversy, especially regarding the use of "sound therapy" as a basic component of treatment. It is the objective of this article to clarify the major differences that exist between these two forms of treatment.

Clinical trial to compare tinnitus masking and tinnitus retraining therapy

2006 ◽  
Vol 126 (sup556) ◽  
pp. 64-69 ◽  
Author(s):  
J.A. Henry ◽  
M.A. Schechter ◽  
T.L. Zaugg ◽  
S. Griest ◽  
P.J. Jastreboff ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Tinnitus Retraining Therapy ◽  
Retraining Therapy ◽  
Tinnitus Masking

Outcomes of Clinical Trial: Tinnitus Masking versus Tinnitus Retraining Therapy

2006 ◽  
Vol 17 (02) ◽  
pp. 104-132 ◽  
Author(s):  
James A. Henry ◽  
Martin A. Schechter ◽  
Tara L. Zaugg ◽  
Susan Griest ◽  
Pawel J. Jastreboff ◽  
...  
Keyword(s):  
Military Veterans ◽  
Severity Index ◽  
Tinnitus Retraining Therapy ◽  
Tinnitus Severity ◽  
Retraining Therapy ◽  
Clinically Significant ◽  
Intent To Treat ◽  
Tinnitus Masking ◽  
Controlled Clinical Study ◽  
Time Aware

A controlled clinical study was conducted to evaluate prospectively the clinical efficacy of tinnitus masking (TM) and tinnitus retraining therapy (TRT) in military veterans having clinically significant tinnitus. Qualifying patients were placed into the two groups in an alternating manner (to avoid selection bias), and treatment was administered at 0, 3, 6, 12, and 18 months. Outcomes of treatment were evaluated using three self-administered tinnitus questionnaires (Tinnitus Handicap Inventory, Tinnitus Handicap Questionnaire, Tinnitus Severity Index) and the verbally administered TRT interview forms. Findings are presented from the three written questionnaires, and from two of the interview questions (percentage time aware of, and annoyed by, tinnitus). Outcomes were analyzed on an intent-to-treat basis, using a multilevel modeling approach. Of the 123 patients enrolled, 118 were included in the analysis. Both groups showed significant declines (improvements) on these measures, with the TRT decline being significantly greater than for TM. The greater declines in TRT compared to TM occurred most strongly in patients who began treatment with a "very big" tinnitus problem. When patients began treatment with a "moderate" tinnitus problem, the benefits of TRT compared to TM were more modest.

Therapy-Related Myeloid Sarcoma As a New Diagnostic Entity? A 10-Year Institutional Retrospective Review

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2656-2656
Author(s):  
Taylor Deal ◽  
Uma Borate ◽  
Shuko Harada ◽  
Vishnu Reddy ◽  
Deniz Peker
Keyword(s):  
Breast Cancer ◽  
Myeloid Sarcoma ◽  
Prior History ◽  
Cell Transplant ◽  
Myeloid Neoplasms ◽  
Significant Difference ◽  
Hematological Cancers ◽  
History Of ◽  
Group 2 ◽  
Group 1

Abstract Therapy-related myeloid neoplasms (t-MN) occur as a complication after chemotherapy (CT) and/or radiation therapy (RT) and account for approximately 10 to 20% of all cases of myeloid neoplasms. t-MN often have a high prevalence of adverse-risk karyotypes. Myeloid sarcoma (MS) is a rare form of extramedullary MN with or without coexisting acute myeloid leukemia (AML). It often has similar molecular/genetic features to AML and myelodysplastic syndrome (MDS). Therapy-related MS (t-MS) is a very rare condition and has not been fully studied. We aim to investigate the features of t-MS in comparison to non-therapy-related MS. A retrospective case review between 2003- 2013 was performed after IRB approval. Cases of MS with or without concurrent bone marrow (BM) disease were included in the study. Based on a prior history of therapy for solid or hematological cancers, patients were divided into two groups. Group 1 consisted of MS cases with a history of preceding treatment (t-MS). The remaining cases were included in Group 2. A survival analysis was performed. A total of fifty-four MS cases were included in the study. The age ranged from 25 - 92 years (median age= 56). Male to female ratio was 1.7:1. Thirty-one cases were diagnosed as leukemia cutis, and the remaining were located in other anatomical sites. Sixteen patients had no concurrent BM disease at the time of diagnosis and 17 cases had no prior MN. Cytogenetic and/or FISH data for MS were available for 28 patients. Nineteen patients had normal cytogenetics 3 of which had abnormality via FISH (PML/RARA and MLL gene rearrangements and -7q). Ten of the 54 cases were found to have a prior history of CT and/or RT for solid or hematological cancers (Table 1; Group 1). Cases with prior AML history were included in group 1 (t-MS) if there was evidence of cytogenetic and/or phenotypic evolution from the original tumor. The remaining AML cases were considered relapsed or recurrent disease and included in group 2. The median age in t-MS group was 57 (39 -88 years) and M:F ratio was 1:1. In 10 cases, the most frequent prior solid malignancy was breast cancer (n=4). Five patients had a previous diagnosis of AML of a different subtype with an interval ranging 24-96 months. The overall interval time between the prior therapy and t-MS in all cases was 41 months (ranging from 6 to 126). Eight of 10 cases had no concurrent BM involvement. Molecular studies were available in 7of the 10 patients, and 3 had detectable genetic abnormalities. The treatment for both groups included intensive induction therapy with 7&3 (anthracycline/Ara-C) with or without radiotherapy and various clinical trials. Overall Survival (OS) analysis revealed a significant difference between the two groups (P-value <0.0395). The OS for t-MS patients was significantly shorter at 10 months (ranging 2 to 32; n=10) while compared to 24 months in the remaining 44 patients (1-55 months)Table 1.Group 1 (t-MS)AgeGenderPrior CancerInitial karyotype/FISHPrior TreatmentInterval to MS (m)Location of MSBone marrow diseaseSurvival (m)CytogeneticsFISH164MAML46,XY / normalCT+ SCT32L4NO7Normal-7q239FAML-MDSN/ACT+SCT63Ethmoid sinusNO6*NormalNormal363MAMLt(8;21)CT52Vocal cordNO32NormalNormal457MAMLN/ACT+SCT46SkinAML-MDS2N/AN/A557MAML46,XYCT6SkinAML10Trisomy, tetrasomy and pentasomy of chromosome 8N/A688MLarynx caN/ASurgery+RT124Lymph node (retroperiton)NON/AN/AN/A751FBreast caN/ACT+RT30L3NO◊29NormalNormal845FBreast caN/ACT+RT23Skin (upper abdomen)NO10NormalMLL+981FBreast caN/ACT54Skin (arm)N/A8NormalN/A1043FBreast caN/ACT+RT11Skin (chest)NO◊7N/AN/AMS: Myeloid sarcoma; CT: Chemotherapy; RT: radiotherapy; SCT: stem cell transplant*Patient alive◊Patient developed AML later in the course The results of the current study demonstrate that the epidemiologic features and cytogenetic abnormalities of t-MS are somewhat similar to other MS. Breast cancer is the most commonly associated solid tumor and AML with or without recurrent cytogenetics is the most common hematologic neoplasm associated with t-MS. Despite the similarities, t-MS appears to have a much worse prognosis regardless of the karyotype. Larger scale studies with more extensive molecular analyses are warranted to understand the pathophysiology of this rare disease and to generate more effective treatments. BRAF and RAS testing are being performed and the results will be available by October 1st. Disclosures: Borate: Seattle Genetics, Inc.: Research Funding; Genoptix: Consultancy.

Mindfulness-Based Therapy in the Management of Tinnitus

2022 ◽  
pp. 175-183
Author(s):  
Prashanth Prabhu P.
Keyword(s):  
Cognitive Behavioral Therapy ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
Controlled Trials ◽  
Tinnitus Retraining Therapy ◽  
Attention System ◽  
Retraining Therapy ◽  
Tinnitus Treatment ◽  
Study Designs ◽  
Mindfulness Therapy

Mindfulness-based interventions are one of the recent techniques that have proven to be very useful in tinnitus management. Mindfulness therapy refers to experiencing the present, which helps control the attention system, which significantly contributes to getting relief from the adverse reactions due to tinnitus. Several systematic reviews and randomized controlled trials report relief from tinnitus perception even with the heterogeneity of the patients with mindfulness therapy. The different study designs and outcome measures reported similar results suggesting the efficacy of mindfulness-based training. Thus, psychologists and audiologists dealing with individuals suffering from tinnitus can attempt this technique in management. The mindfulness-based training can be combined with formal Cognitive Behavioral Therapy (CBT) and Tinnitus Retraining Therapy (TRT) approaches to enhance tinnitus treatment.

scholarly journals Treatment efficacy of tolterodine versus belladonna mixture in children with idiopathic overactive bladder

2019 ◽  
Vol 2 (2) ◽  
pp. e000046
Author(s):  
Zheming Xu ◽  
Dehua Wu ◽  
Chang Tao ◽  
Juan Zhou ◽  
Zhihui Zheng ◽  
...  
Keyword(s):  
Side Effects ◽  
Overactive Bladder ◽  
Anticholinergic Drug ◽  
Days Of Therapy ◽  
Voiding Diary ◽  
History Of ◽  
Mixture Group ◽  
Group 2 ◽  
Anticholinergic Side Effects ◽  
Group 1

ObjectivesChildren with symptoms of urinary urgency, frequency and incontinence are common in the clinic. The aim of the present study was to compare the tolerability and efficacy of tolterodine, a bladder-selective muscarinic receptor antagonist, with belladonna mixture, a traditional anticholinergic drug, in the treatment of idiopathic overactive bladder in children.MethodsChildren aged 5–10 years with a history of diurnal urgency, frequency and incontinence were randomly divided into two groups. Participants in group 1 were given tolterodine 1 mg twice a day for 14 days. If the results were found to be mildly ineffective, after the first 14 days of therapy, prolonged course with 2 mg twice a day was given. In group 2, the children were treated with belladonna mixture 5 mL twice a day for 14 days. Anticholinergic side effects were recorded during the therapy and efficacy was evaluated with voiding diary recorded by the parents at the beginning and end of therapy.ResultsA total of 668 cases were included in this study and 334 for each 25 group (496 boys and 172 girls). Evident anticholinergic side effects which could cease the therapy, such as dry mouth, constipation, mood changes, irritability, and so on, exhibited only on 2% of participants in the tolterodine group but 69% in the belladonna mixture group (p≤0.05). The symptoms of detrusor overactivity disappeared or significantly improved in 80% of children in the tolterodine group and 37% in the belladonna mixture (p≤0.05) group.ConclusionsTolterodine had better tolerability and efficacy than belladonna mixture in treating overactive bladder in children.

Abstract 12193: Cardiovascular Toxicity of Carfilzomib on Vascular Tone, Vascular Reactivity and Endothelial Function

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Tiziano Scarabelli ◽  
Mara Gavazzoni ◽  
Carol Chen-Scarabelli ◽  
Gagan Sahni ◽  
Louis Saravolatz ◽  
...  
Keyword(s):  
Vascular Tone ◽  
Vascular Reactivity ◽  
Coronary Spasm ◽  
Prior History ◽  
Organ Bath ◽  
Clinical Safety ◽  
History Of ◽  
Group 2 ◽  
In Vitro Effects

Background: Carfilzomib (CFZ) is a new proteasome inhibitor used for the treatment of Multiple Myeloma (MM). Cardiac failure events (7.2%) and myocardial ischemia have occurred following administration CFZ. Infusion reactions also include chest thightness and angina of unknown mechanism. Aim of study: To investigate whether CFZ exerts in vitro effects on vascular tone and reactivity in an isolated experimental model of rabbit thoracic aortic-strips. Methods and Results: We evaluated first the effect of single injections of CFZ on the basal tone of isolated aortic strips (n= 6) placed in 10 ml organ bath at 37°C containing Krebs-Henseleit solution. Vasoconscriction, as documented by an overall increase in tension of 0.5 g, was observed with increasing concentrations of CFZ (from 1 x 10-9 to 10 -7 mol/L; p:0.041). In a second set of experiments, the effect of three different spasmogenic agents [potassium chloride (KCl) (n= 6), noradrenaline (NA) (n= 6), and angiontensin II (A) (n= 6)] on naive aortic strips (group 1) was compared to that on aortic strips pretrated for 60 minutes with CFZ at a concentration of 15 nmol/L (group 2). Pretreatment with CFZ resulted in amplified vasocostriction (2.4±0.4 g vs 2.1±0.3 g for KCl administration; 2.5±0.3 g vs 2.0±0.2 g for NA; 2.6±0.2 g vs 2.0±0.2 g for A; all p<0.005) and impaired vasodilation following administration of nitroglycerin (NTG) on the plateau of contraction induced by each spasmogenic agent (100% vs 82% for KCl; 100% vs 67% for NA and 100% vs 51% for A; all p<0.05). Finally, aortic strips pretreated with CFZ exhibited impaired relaxation, as compared to naive strips (100 % versus 40% in tension reduction; p:0.028), following administration of acetylcholine (Ach), an endothelium-dependent vasodilating agent, on the plateau of NA contraction. Conclusions: CFZ increased the resting vasoconstricting tone and amplified the spasmogenic effect of different agents. Moreover, preincubation with CFZ decreased the anti-spasmogenic activity of NTG and reduced by over 50% the vasodilating effect of Ach, suggesting that CFZ can impair vasodilation by inducing endothelial dysfunction. Further studies are warranted to establish its clinical safety in patients with known CAD and prior history of coronary spasm.

Clinical efficacy of tinnitus retraining therapy and cognitive behavioural therapy in the treatment of subjective tinnitus: a systematic review

2014 ◽  
Vol 128 (12) ◽  
pp. 1028-1033 ◽  
Author(s):  
R Grewal ◽  
P M Spielmann ◽  
S E M Jones ◽  
S S M Hussain
Keyword(s):  
Systematic Review ◽  
Cognitive Behavioural Therapy ◽  
Behavioural Therapy ◽  
Tinnitus Retraining Therapy ◽  
Validated Questionnaires ◽  
Cognitive Behavioural ◽  
Retraining Therapy ◽  
Randomised Control Trials ◽  
Human Participants ◽  
Tinnitus Masking

AbstractObjective:This study aimed to compare the outcomes of two frequently employed interventions for the management of tinnitus: tinnitus retraining therapy and cognitive behavioural therapy.Method:A systematic review of literature published up to and including February 2013 was performed. Only randomised control trials and studies involving only human participants were included.Results:Nine high-quality studies evaluating the efficacy of tinnitus retraining therapy and cognitive behavioural therapy were identified. Of these, eight assessed cognitive behavioural therapy relative to a no-treatment control and one compared tinnitus retraining therapy to tinnitus masking therapy. Each study used a variety of standardised and validated questionnaires. Outcome measures were heterogeneous, but both therapies resulted in significant improvements in quality of life scores. Depression scores improved with cognitive behavioural therapy.Conclusion:Both cognitive behavioural therapy and tinnitus retraining therapy are effective for tinnitus, with neither therapy being demonstrably superior. Further research using standardised, validated questionnaires is needed so that objective comparisons can be made.

scholarly journals Utility of 24-hour ambulatory blood pressure monitoring in potential living kidney donors

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Nabeel Aslam ◽  
Sobia H. Memon ◽  
Hani Wadei ◽  
Elizabeth R. Lesser ◽  
Shehzad K. Niazi
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Monitoring ◽  
Kidney Donation ◽  
Prior History ◽  
Newly Diagnosed ◽  
Pressure Monitoring ◽  
Kidney Donors ◽  
History Of ◽  
Group 2 ◽  
New Diagnosis

Abstract Introduction Hypertension (HTN) is a risk factor for cardiovascular disease; therefore, it is imperative to risk stratify potential kidney donors during evaluation. Clinic blood pressure (CBP) measurement is inaccurate in assessing presence or absence of HTN. There is paucity of data about utility of 24-h ambulatory blood pressure monitoring (ABPM) during kidney donor evaluation. Methods 24-h ABPM is performed on all kidney donors at Mayo Clinic Florida. We conducted retrospective review of 264 consecutive potential kidney donors from 1/1/2012 to 12/31/2017. Demographic, comorbid conditions, laboratory results and 24-h ABPM data were collected. Subjects were divided into two groups: Group1: Subjects with no prior history of HTN and new diagnosis of HTN using 24-h ABPM; Group 2: Subjects with no prior history of hypertension and normal BP on 24-h ABPM. Results Baseline demographic included mean age 46.40 years, 39% males, 78.4% Caucasians, and mean BMI was 26.94. Twenty one subjects (8.0%) had prior diagnosis of HTN. Among 243 subjects without prior HTN, 62 (25.5%) were newly diagnosed with HTN using 24-h ABPM. CBP was high only in 27 out of 62 (43.6%) of newly diagnosed HTN subjects. Thirty-five subjects (14.4%) had masked HTN and 14 subjects (5.8%) had white-coat HTN. Newly diagnosed hypertensive subjects were more likely to be males as compared to Group 2 (53.2% vs 34.3% P = 0.008). There was a trend of more non-Caucasians subjects (30.6% vs 19.9% P = 0.08) and more active smokers (17.7% vs 11.6%, P = 0.054) in Group1 as compared to Group 2. Only 17 (27.4%) out of 62 newly diagnosed hypertensive subjects were deemed suitable for kidney donation as compared to 105 (58.0%) out of 181 normotensive subjects (P < 0.001). Conclusion In our cohort, use of ABPM resulted in new diagnosis of HTN in 1 out of 4 potential kidney donors. Newly diagnosed HTN was more common in men, those with non-Caucasian race, and in active smokers. There was a significantly reduced acceptance rate for kidney donation among newly diagnosed HTN subjects. Further studies are needed to determine the value of 24-h ABPM among these high risk groups.

Sign in / Sign up

Export Citation Format

Share Document